Home » Stocks » CRMD

CorMedix, Inc. (CRMD)

Stock Price: $8.15 USD -0.36 (-4.23%)
Updated May 10, 2021 4:00 PM EDT - Market closed
After-hours: $8.11 -0.04 (-0.49%) May 10, 6:28 PM
Market Cap 309.90M
Revenue (ttm) 239,231
Net Income (ttm) -22.03M
Shares Out 28.56M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $8.15
Previous Close $8.51
Change ($) -0.36
Change (%) -4.23%
Day's Open 8.43
Day's Range 7.99 - 8.44
Day's Volume 294,496
52-Week Range 3.47 - 18.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

BERKELEY HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

1 week ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

1 month ago - GlobeNewsWire

CorMedix (CRMD) delivered earnings and revenue surprises of 17.39% and -11.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time

1 month ago - GlobeNewsWire

NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are advised to contac...

1 month ago - PRNewsWire

BERKELEY HEIGHTS, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

1 month ago - GlobeNewsWire

NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc.  ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are advised to conta...

1 month ago - PRNewsWire

BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

1 month ago - GlobeNewsWire

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CorMedix, Inc.  ("CorMedix" or the "Company") (NASDAQ: CRMD).  Such investors are advised to cont...

1 month ago - PRNewsWire

BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

1 month ago - GlobeNewsWire

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), Surface Oncology, Inc. (NASDAQ: SURF) and CorMedix Inc. (NASDAQ: CRMD) are among the biggest movers among health care stocks Tuesday.

Other stocks mentioned: ANPC, SURF
2 months ago - Benzinga

BERKELEY HEIGHTS, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

2 months ago - GlobeNewsWire

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CorMedix Inc. ("CorMedix" or the "Company") (NASDAQ: CRMD). Such investors are advised to contact ...

2 months ago - PRNewsWire

The FDA gave a thumbs-down to CorMedix's antibacterial/anti-fungal catheter lock.

2 months ago - The Motley Fool

The FDA has issued a Complete Response Letter for CorMedix Inc's (NASDAQ: CRMD) marketing application seeking approval for DefenCath (taurolidine/heparin catheter lock solution) for catheter-related blo...

2 months ago - Benzinga

BERKELEY HEIGHTS, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

2 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preventi...

3 months ago - GlobeNewsWire

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

5 months ago - Zacks Investment Research

Does CorMedix (CRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

5 months ago - Zacks Investment Research

BERKELEY HEIGHTS, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preventi...

5 months ago - GlobeNewsWire

Candidate could get approval. But IP not very strong.

5 months ago - Seeking Alpha

CorMedix Inc. (CRMD) CEO Khoso Baluch on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

CorMedix (CRMD) delivered earnings and revenue surprises of 15.38% and 116.28%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

CorMedix's (CRMD) CEO Khoso Baluch On Q3 2020 Results - Quick Version Earnings Call Transcript

6 months ago - Seeking Alpha

Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Seasoned industry veteran with decades of strategic and commercial leadership experi...

6 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preventi...

6 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preventi...

7 months ago - GlobeNewsWire

It may be unusual to see nearly a 10% gain from a single analyst call. When analysts call for upside of more than 100% it can attract some attention.

7 months ago - 24/7 Wall Street

Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Seasoned industry veteran with decades of strategic and commercial leadership experi...

7 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preve...

8 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., Aug. 31, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preven...

8 months ago - GlobeNewsWire

CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

CorMedix's (CRMD) CEO Khoso Baluch on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

CorMedix (CRMD) delivered earnings and revenue surprises of 41.67% and -83.16%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time

9 months ago - GlobeNewsWire

Cormedix (AMEX: CRMD) unveils its next round of earnings this Monday, August 10.

9 months ago - Benzinga

BERKELEY HEIGHTS, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preven...

9 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD) (the “Company”), a biopharmaceutical company focused on developing and commercializing therapeutic product...

9 months ago - GlobeNewsWire

CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Priority Review of NDA Requested Priority Review of NDA Requested

10 months ago - GlobeNewsWire

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

11 months ago - Zacks Investment Research

CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

CorMedix (CRMD) delivered earnings and revenue surprises of 8.70% and -48.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

BERKELEY HEIGHTS, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American:  CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preven...

11 months ago - GlobeNewsWire

BERKELEY HEIGHTS, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preve...

1 year ago - GlobeNewsWire

Top Ranked Momentum Stocks to Buy for April 22nd

Other stocks mentioned: ASC, FUV, OVID
1 year ago - Zacks Investment Research

BERKELEY HEIGHTS, N.J., April 22, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preve...

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor CorMedix

1 year ago - Zacks Investment Research

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology... [Read more...]

Industry
Biotechnology
IPO Date
Mar 25, 2010
CEO
Khoso Baluch
Employees
35
Stock Exchange
NASDAQ
Ticker Symbol
CRMD
Full Company Profile

Financial Performance

In 2020, CorMedix's revenue was $239,231, a decrease of -15.55% compared to the previous year's $283,266. Losses were -$22.03 million, 34.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for CorMedix stock is "Buy." The 12-month stock price forecast is 20.90, which is an increase of 156.44% from the latest price.

Price Target
$20.90
(156.44% upside)
Analyst Consensus: Buy